"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Following administration of 100 mg twice daily for three consecutive days, plasma levels of VERMOX® (mebendazole) and its primary metabolite, the 2-amine, do not exceed 0.03 µg/mL and 0.09 µg/mL, respectively. All metabolites are devoid of anthelmintic activity. In man, approximately 2% of administered VERMOX® (mebendazole) is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite.
Mode of Action
VERMOX® (mebendazole) inhibits the formation of the worms' microtubules and causes the worms' glucose depletion.
Last reviewed on RxList: 5/13/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Vermox Information
Vermox - User Reviews
Vermox User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.